BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 10809402)

  • 1. Altered redox state of platelet coenzyme Q10 in Parkinson's disease.
    Götz ME; Gerstner A; Harth R; Dirr A; Janetzky B; Kuhn W; Riederer P; Gerlach M
    J Neural Transm (Vienna); 2000; 107(1):41-8. PubMed ID: 10809402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A possible role of coenzyme Q10 in the etiology and treatment of Parkinson's disease.
    Shults CW; Haas RH; Beal MF
    Biofactors; 1999; 9(2-4):267-72. PubMed ID: 10416040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Platelet monoamine oxidase B activity in "de novo" and l-dopa treated parkinsonian patients and controls.
    Kuhn W; Müller T; Gerstner A; Winkel R; Goetz ME
    Can J Neurol Sci; 1998 Aug; 25(3):249-51. PubMed ID: 9706728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Altered redox status of coenzyme Q9 reflects mitochondrial electron transport chain deficiencies in Caenorhabditis elegans.
    Vasta V; Sedensky M; Morgan P; Hahn SH
    Mitochondrion; 2011 Jan; 11(1):136-8. PubMed ID: 20849980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma levels and redox status of coenzyme Q10 in infants and children.
    Menke T; Niklowitz P; Schlüter B; Weber M; Buschatz D; Trowitzsch E; Andler W
    Biofactors; 2004; 20(3):173-81. PubMed ID: 15665387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ubiquinone (coenzyme q10) and mitochondria in oxidative stress of parkinson's disease.
    Ebadi M; Govitrapong P; Sharma S; Muralikrishnan D; Shavali S; Pellett L; Schafer R; Albano C; Eken J
    Biol Signals Recept; 2001; 10(3-4):224-53. PubMed ID: 11351130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A dose-ranging study of selegiline in patients with Parkinson's disease: effect of platelet monoamine oxidase activity.
    Andreu N; Damase-Michel C; Senard JM; Rascol O; Montastruc JL
    Mov Disord; 1997 May; 12(3):293-6. PubMed ID: 9159721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized, double-blind, placebo-controlled pilot trial of reduced coenzyme Q10 for Parkinson's disease.
    Yoritaka A; Kawajiri S; Yamamoto Y; Nakahara T; Ando M; Hashimoto K; Nagase M; Saito Y; Hattori N
    Parkinsonism Relat Disord; 2015 Aug; 21(8):911-6. PubMed ID: 26054881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit.
    ; Beal MF; Oakes D; Shoulson I; Henchcliffe C; Galpern WR; Haas R; Juncos JL; Nutt JG; Voss TS; Ravina B; Shults CM; Helles K; Snively V; Lew MF; Griebner B; Watts A; Gao S; Pourcher E; Bond L; Kompoliti K; Agarwal P; Sia C; Jog M; Cole L; Sultana M; Kurlan R; Richard I; Deeley C; Waters CH; Figueroa A; Arkun A; Brodsky M; Ondo WG; Hunter CB; Jimenez-Shahed J; Palao A; Miyasaki JM; So J; Tetrud J; Reys L; Smith K; Singer C; Blenke A; Russell DS; Cotto C; Friedman JH; Lannon M; Zhang L; Drasby E; Kumar R; Subramanian T; Ford DS; Grimes DA; Cote D; Conway J; Siderowf AD; Evatt ML; Sommerfeld B; Lieberman AN; Okun MS; Rodriguez RL; Merritt S; Swartz CL; Martin WR; King P; Stover N; Guthrie S; Watts RL; Ahmed A; Fernandez HH; Winters A; Mari Z; Dawson TM; Dunlop B; Feigin AS; Shannon B; Nirenberg MJ; Ogg M; Ellias SA; Thomas CA; Frei K; Bodis-Wollner I; Glazman S; Mayer T; Hauser RA; Pahwa R; Langhammer A; Ranawaya R; Derwent L; Sethi KD; Farrow B; Prakash R; Litvan I; Robinson A; Sahay A; Gartner M; Hinson VK; Markind S; Pelikan M; Perlmutter JS; Hartlein J; Molho E; Evans S; Adler CH; Duffy A; Lind M; Elmer L; Davis K; Spears J; Wilson S; Leehey MA; Hermanowicz N; Niswonger S; Shill HA; Obradov S; Rajput A; Cowper M; Lessig S; Song D; Fontaine D; Zadikoff C; Williams K; Blindauer KA; Bergholte J; Propsom CS; Stacy MA; Field J; Mihaila D; Chilton M; Uc EY; Sieren J; Simon DK; Kraics L; Silver A; Boyd JT; Hamill RW; Ingvoldstad C; Young J; Thomas K; Kostyk SK; Wojcieszek J; Pfeiffer RF; Panisset M; Beland M; Reich SG; Cines M; Zappala N; Rivest J; Zweig R; Lumina LP; Hilliard CL; Grill S; Kellermann M; Tuite P; Rolandelli S; Kang UJ; Young J; Rao J; Cook MM; Severt L; Boyar K
    JAMA Neurol; 2014 May; 71(5):543-52. PubMed ID: 24664227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of coenzyme Q10 intake on endogenous coenzyme Q content, mitochondrial electron transport chain, antioxidative defenses, and life span of mice.
    Sohal RS; Kamzalov S; Sumien N; Ferguson M; Rebrin I; Heinrich KR; Forster MJ
    Free Radic Biol Med; 2006 Feb; 40(3):480-7. PubMed ID: 16443163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Redox status of plasma coenzyme Q10 indicates elevated systemic oxidative stress in Parkinson's disease.
    Sohmiya M; Tanaka M; Tak NW; Yanagisawa M; Tanino Y; Suzuki Y; Okamoto K; Yamamoto Y
    J Neurol Sci; 2004 Aug; 223(2):161-6. PubMed ID: 15337618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The need for levodopa as an end point of Parkinson's disease progression in a clinical trial of selegiline and alpha-tocopherol. Parkinson Study Group.
    LeWitt P; Oakes D; Cui L
    Mov Disord; 1997 Mar; 12(2):183-9. PubMed ID: 9087976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum levels of coenzyme Q10 in patients with Parkinson's disease.
    Jiménez-Jiménez FJ; Molina JA; de Bustos F; García-Redondo A; Gómez-Escalonilla C; Martínez-Salio A; Berbel A; Camacho A; Zurdo M; Barcenilla B; Enríquez de Salamanca R; Arenas J
    J Neural Transm (Vienna); 2000; 107(2):177-81. PubMed ID: 10847558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.
    Lyytinen J; Kaakkola S; Ahtila S; Tuomainen P; Teräväinen H
    Mov Disord; 1997 Jul; 12(4):497-505. PubMed ID: 9251066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Coenzyme Q10 levels correlate with the activities of complexes I and II/III in mitochondria from parkinsonian and nonparkinsonian subjects.
    Shults CW; Haas RH; Passov D; Beal MF
    Ann Neurol; 1997 Aug; 42(2):261-4. PubMed ID: 9266740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Coenzyme Q10 in Parkinson's disease. Symptomatic or neuroprotective effects?].
    Storch A
    Nervenarzt; 2007 Dec; 78(12):1378-82. PubMed ID: 17508194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic effects of coenzyme Q10 (CoQ10) and reduced CoQ10 in the MPTP model of Parkinsonism.
    Cleren C; Yang L; Lorenzo B; Calingasan NY; Schomer A; Sireci A; Wille EJ; Beal MF
    J Neurochem; 2008 Mar; 104(6):1613-21. PubMed ID: 17973981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Coenzyme Q10 supplementation on mitochondrial electron transport chain activity and mitochondrial oxidative stress in Coenzyme Q10 deficient human neuronal cells.
    Duberley KE; Heales SJ; Abramov AY; Chalasani A; Land JM; Rahman S; Hargreaves IP
    Int J Biochem Cell Biol; 2014 May; 50():60-3. PubMed ID: 24534273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does high-dose coenzyme Q10 improve oxidative damage and clinical outcomes in Parkinson's disease?
    Seet RC; Lim EC; Tan JJ; Quek AM; Chow AW; Chong WL; Ng MP; Ong CN; Halliwell B
    Antioxid Redox Signal; 2014 Jul; 21(2):211-7. PubMed ID: 24410614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validation and application of an HPLC-EC method for analysis of coenzyme Q10 in blood platelets.
    Miles MV; Tang PH; Miles L; Steele PE; Moye MJ; Horn PS
    Biomed Chromatogr; 2008 Dec; 22(12):1403-8. PubMed ID: 18655217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.